CN101537008A - Livestock cefquinome bletilla striata bioadhesive slow-release capsules - Google Patents
Livestock cefquinome bletilla striata bioadhesive slow-release capsules Download PDFInfo
- Publication number
- CN101537008A CN101537008A CN200810052449A CN200810052449A CN101537008A CN 101537008 A CN101537008 A CN 101537008A CN 200810052449 A CN200810052449 A CN 200810052449A CN 200810052449 A CN200810052449 A CN 200810052449A CN 101537008 A CN101537008 A CN 101537008A
- Authority
- CN
- China
- Prior art keywords
- cefquinome
- bletilla striata
- bletillae
- drug
- release capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 title claims abstract description 35
- 229950009592 cefquinome Drugs 0.000 title claims abstract description 35
- 239000000227 bioadhesive Substances 0.000 title claims abstract description 30
- 239000002775 capsule Substances 0.000 title claims abstract description 26
- 241001313857 Bletilla striata Species 0.000 title claims abstract description 24
- 244000144972 livestock Species 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000000273 veterinary drug Substances 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims abstract description 3
- 239000003292 glue Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000004062 sedimentation Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003640 drug residue Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- -1 dry about 60 °C Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000007227 biological adhesion Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- RSJOBNMOMQFPKQ-ZVGUSBNCSA-L copper;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O RSJOBNMOMQFPKQ-ZVGUSBNCSA-L 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of veterinary drugs, and particularly relates to a veterinary drug of cefquinome bletilla striata bioadhesive slow-release capsule prepared by using cefquinome and bletilla striata as raw materials. An aqueous extraction and alcohol sedimentation method is adopted to extract the bletilla striata; the ratio of the cefquinome to the bletilla striata is 1:3; a 10 percent PVP ethanol solution is used as an adhesive; and the drug is made into 20 mesh grains and is filled in capsules. The contents of the cefquinome bletilla striata bioadhesive slow-release capsules can prolong the time for the detention of the drug at focuses, improve the local concentration of the drug in lesions, and have excellent bioadhesive property as well as the same drug release characteristic as a slow-release preparation.
Description
Technical field
The invention belongs to the technical field of veterinary drug, particularly relating to cefquinome, the Pseudobulbus Bletillae (Rhizoma Bletillae) is feedstock production veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules.
Background technology
Culture towards intensive and intensive direction and develop along with the animal husbandry of China, the continuous expansion of scale is cultured in animal husbandry, ensures that the quality safety of animal husbandry product has become the present major issue that we need solve.At present, the problem that China's animal product mainly exists has: the one, and the threat of dangerous disease; The 2nd, drug residue.Wherein the drug residue in the animal food has jeopardized people ' s health.Therefore, rationally using animal veterinary drug and health product to control eqpidemic disease and drug residue in the herding production process, is the major issue that needs solution at present.
Bioadhesive drug delivery system has and can be detained the long period on mucosa, directly with the advantages such as focus of drug release at bacterial infection, improves curative effect of medication when reducing drug dose, alleviates side effects of pharmaceutical drugs.Bioadhesive drug delivery system is that medicine adheres to mucous epithelium by means of some macromolecular material to biological mucosa generation special adhesion power, thereby prolong drug makes medicine bring into play therapeutical effect better in the stop and the release time of corresponding site.The biologic adhesion preparation technology can be made medicine multiple dosage forms such as powder, tablet, membrane, capsule, is applicable to the mucosa delivery of different parts, as oral cavity, digestive tract, nasal mucosa etc.At beginning of the eighties late 1970s, Nagai adopts the adhesiveness polymer as anti-inflammatory steroid class pharmaceutical carrier first, and the topical treatment aphtha obtains better therapeutic effect.Types such as it is synthetic, natural and semi-synthetic that bioadhesive material has, desirable bioadhesive material should meet avirulence, excellent biological compatibility, easily and medicament mixed, requirements such as not influencing medicine assay, have good Release Performance, be cheap and easy to get.The natural biological adhesion material has: gelatin, pectin, arabic gum, sodium alginate etc.Synthetic bioadhesive material major part is polyacrylic acid or cellulose derivative, as sodium carboxymethyl cellulose (CMC-Na), hypromellose (HPMC), hydroxypropyl cellulose (HPC), polyvinyl alcohol (PEG) etc.Nontoxic, the good biocompatibility of natural material, but adhesiveness and Release Performance are undesirable; The adhesiveness and the Release Performance of synthetic material are better, and the price height, safety is undesirable.Therefore, there be limited evidence currently of has bioadhesive material to reach requirement fully.
Summary of the invention
The objective of the invention is to cefquinome, the Pseudobulbus Bletillae (Rhizoma Bletillae) at the problems referred to above is feedstock production veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules, thereby prolong drug reaches valid density in the time of Entogastric lingering at gastric mucosa layer or surface epithelial cell.
For reach purpose of the present invention we to select cefquinome, the Pseudobulbus Bletillae (Rhizoma Bletillae) be feedstock production bioadhesive slow release capsule.The Pseudobulbus Bletillae (Rhizoma Bletillae) is the dry tuber of the orchid Pseudobulbus Bletillae (Rhizoma Bletillae), bitter in the mouth, sweet, puckery, and cold nature is traditional hemorrhage, has the effect of hemostasis convergence, detumescence and promoting granulation.Modern study shows, the Pseudobulbus Bletillae (Rhizoma Bletillae) has pharmacological actions widely such as antiulcer, anti-alimentary tract are hemorrhage, prevention intestinal adhesion, artificial embolism, antitumor.
A kind of phlegmatic temperament that Pseudobulbus Bletillae (Rhizoma Bletillae) glue system obtains through water extract-alcohol precipitation from the Pseudobulbus Bletillae (Rhizoma Bletillae), be the powder of white or yellowish-brown, tasteless, odorless, water soluble forms viscosity solution, be insoluble to ethanol, chemistry constitutes genus mucopolysaccharide macromolecular compound, is polymerized by 4 molecule mannose and 1 molecule glucose, and it is 183 that gel filtration records mean molecule quantity, 000, it is 2,881,000 that viscosimetry is measured viscosity-average molecular weight.Pseudobulbus Bletillae (Rhizoma Bletillae) glue is as the unique characteristics in aspects such as medicinal substrate and pharmaceutical carrier, for example, play the effect of suspending in preparation suspension type lotion, liniment, Pseudobulbus Bletillae (Rhizoma Bletillae) glue also day by day increases as the substrate of emulsifying agent, ultrasonic coupling agent, gel, facial cream, facial film with as the application of aspects such as the additive of the binding agent of tablet, eye drop and liniment.Pseudobulbus Bletillae (Rhizoma Bletillae) glue is as pharmaceutical carrier, can prolong the holdup time of principal agent, have characteristics such as functional slow-release, local anelasticity, self degradability, nonirritant, have no side effect, and can reduce the toxicity of contained medicine, and cheap, aboundresources, exploitation is worth having preferably aspect preparation targeting drug delivery system or slow release, the controlled release preparation.
The present invention utilizes the therapeutical effect of Pseudobulbus Bletillae (Rhizoma Bletillae) glue, and the characteristics that have functional slow-release, local adhesive retention as adjuvant, veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules is provided, it is characterized in that with Pseudobulbus Bletillae (Rhizoma Bletillae) glue be adhesion material, cefquinome is a model drug, 10%PVP (polyvinylpyrrolidone) alcoholic solution is made binding agent, preparation livestock cefquinome bletilla striata bioadhesive slow-release capsules.
Described veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules, it is characterized in that, Pseudobulbus Bletillae (Rhizoma Bletillae) rubber powder is broken, cross 100 mesh sieves, add cefquinome, cefquinome is 1: 3 with Pseudobulbus Bletillae (Rhizoma Bletillae) glue ratio, abundant mixing, and 10%PVP (polyvinylpyrrolidone) alcoholic solution is made binding agent, make 20 order granules, dry about 60 ℃, granulate incapsulates.
Described veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules, its feature also is, the preparation method of Pseudobulbus Bletillae (Rhizoma Bletillae) glue: get Pseudobulbus Bletillae (Rhizoma Bletillae) powder and be broken into coarse grain, add as 6-8 times of distilled water of medical material amount, flood half an hour with 60 ℃ of insulations, stir at any time, with four layers of filtered through gauze; The medicinal residues adding distil water repeats above operation 4 times, merging filtrate again, concentrate, add 95% ethanol and make and contain the alcohol amount and reach 70%, separate out a large amount of white flocculent deposits, leave standstill a night, filter next day, reclaims ethanol, the collecting precipitation thing with 95% washing with alcohol 3 times, volatilizes ethanol, oven dry about 80 ℃, weigh, pulverize, Pseudobulbus Bletillae (Rhizoma Bletillae) glue extraction ratio can reach 22%.
The invention effect: Pseudobulbus Bletillae (Rhizoma Bletillae) glue is the mucopolysaccharide macromolecular compound, is polymerized by 4 molecule mannose and 1 molecule glucose, can be used as pharmaceutical carrier, the prolong drug holdup time, improves medication effect.Have characteristics such as self degradability, nonirritant, have no side effect, cheap and easy to get, aboundresources, the exploitation that has as pharmaceutical carrier is worth;
The livestock cefquinome bletilla striata bioadhesive slow-release capsules is carried out interior evaluating: adopt left drug amount in the determined by ultraviolet spectrophotometry rat stomach tissue.Adopt high-efficient liquid phase chromatogram technique analysis blood drug level.Experimental result shows, take capsule 's content after 2 hours in the rat stomach tissue medicine retention rate significantly improved the local concentration of medicine significantly greater than the retention rate of cefquinome at gastric.The pharmacokinetics experiment shows that this capsule particle absorbs with first-rate.Left drug scale at the animal gastric after the administration is bright, but cefquinome bletilla striata bioadhesive slow-release capsules content prolong drug improves the local concentration of medicine at gastric tissue in the holdup time of gastric, has good bioadhesive.
Cefquinome bletilla striata bioadhesive slow-release capsules content has the drug release characteristic of slow releasing preparation, thereby prolonged delay and the release time of medicine at corresponding site, make medicine bring into play therapeutical effect better, also improved whole bioavailability, and obviously improved curative effect of medication and suffered from the compliance of raiseeing.
The specific embodiment
Embodiment 1: preparation cefquinome bletilla striata bioadhesive slow-release capsules
The preparation of a, Pseudobulbus Bletillae (Rhizoma Bletillae) glue: Pseudobulbus Bletillae (Rhizoma Bletillae) 5kg, pulverize adding distil water 35L, 60 ℃ of insulation dippings of heating in water bath, stir, extracting solution is through four layers of filtered through gauze, and medicinal residues are adding distil water again, repeated impregnations, merge filtrate several times, concentrate, add 95% ethanol and make and contain the alcohol amount and reach 70%, separate out a large amount of white flocculent deposits, leave standstill a night, filter next day, reclaims ethanol, the collecting precipitation thing, with washing with alcohol 3 times, volatilize ethanol, oven dry about 80 ℃, weigh, pulverize, can get Pseudobulbus Bletillae (Rhizoma Bletillae) glue 1.09kg; Pseudobulbus Bletillae (Rhizoma Bletillae) glue: character is yellow dry powder, and tasteless odorless is insoluble to ethanol, and is water-soluble, is stiff colloidal.Alpha-Naphthol concentrated sulphuric acid and the experiment of alkaline cupric tartrate test solution are positive reaction, and this product contains alcohol-insoluble substances and is no less than 80%.
B, preparation cefquinome bletilla striata bioadhesive slow-release capsules: get Pseudobulbus Bletillae (Rhizoma Bletillae) glue 0.9kg, cefquinome 0.3kg, Pseudobulbus Bletillae (Rhizoma Bletillae) rubber powder is broken, add cefquinome after crossing 100 mesh sieves, fully mixing is got 10%PVP (polyvinylpyrrolidone) alcoholic solution and is made binding agent, makes 20 order granules, dry about 60 ℃, granulate incapsulates, and promptly gets the cefquinome bletilla striata bioadhesive slow-release capsules.
Embodiment 2: the cefquinome bletilla striata bioadhesive slow-release capsules for preparing is mainly used in the mammitis of cow that the treatment escherichia coli cause, the porcine respiratory disease that pasteurella multocida or Actinobacillus pleuropneumoniae cause.Administering mode is the spice administration, cattle 1mg/kg body weight 1 logotype on the one 2 days; Pig 2～3mg/kg body weight 1 logotype on the one 3 days.B-lactam antibiotics animal hypersensitive is banned use of this product.
Claims (3)
1, veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules is characterized in that with Pseudobulbus Bletillae (Rhizoma Bletillae) glue be adhesion material, and cefquinome is a model drug, and alcoholic solution is made binding agent, preparation cefquinome bletilla striata bioadhesive slow-release capsules.
2, veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules according to claim 1, Pseudobulbus Bletillae (Rhizoma Bletillae) rubber powder is broken, cross 100 mesh sieves, add cefquinome, cefquinome is 1: 3 with Pseudobulbus Bletillae (Rhizoma Bletillae) glue ratio, abundant mixing, 10%PVP (polyvinylpyrrolidone) alcoholic solution is made binding agent, makes 20 order granules, and is dry about 60 ℃, granulate incapsulates.
3, veterinary drug cefquinome bletilla striata bioadhesive slow-release capsules according to claim 1, its feature also is, the preparation method of Pseudobulbus Bletillae (Rhizoma Bletillae) glue: get Pseudobulbus Bletillae (Rhizoma Bletillae) powder and be broken into coarse grain, add as 6-8 times of distilled water of medical material amount, flood half an hour with 60 ℃ of insulations, stir at any time, with four layers of filtered through gauze; The medicinal residues adding distil water repeats above operation 4 times, merging filtrate again, concentrate, add 95% ethanol and make and contain the alcohol amount and reach 70%, separate out a large amount of white flocculent deposits, leave standstill a night, filter next day, reclaims ethanol, the collecting precipitation thing with 95% washing with alcohol 3 times, volatilizes ethanol, oven dry about 80 ℃, weigh, pulverize, Pseudobulbus Bletillae (Rhizoma Bletillae) glue extraction ratio can reach 22%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810052449A CN101537008A (en) | 2008-03-17 | 2008-03-17 | Livestock cefquinome bletilla striata bioadhesive slow-release capsules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810052449A CN101537008A (en) | 2008-03-17 | 2008-03-17 | Livestock cefquinome bletilla striata bioadhesive slow-release capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101537008A true CN101537008A (en) | 2009-09-23 |
Family
ID=41120549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810052449A Pending CN101537008A (en) | 2008-03-17 | 2008-03-17 | Livestock cefquinome bletilla striata bioadhesive slow-release capsules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101537008A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705976A (en) * | 2014-01-09 | 2014-04-09 | 山东省淡水渔业研究院 | Composite bone repair material and preparation method thereof |
| CN104693247A (en) * | 2015-01-22 | 2015-06-10 | 武汉市第一医院 | Method for preparing Bletilla striata gelatin |
-
2008
- 2008-03-17 CN CN200810052449A patent/CN101537008A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705976A (en) * | 2014-01-09 | 2014-04-09 | 山东省淡水渔业研究院 | Composite bone repair material and preparation method thereof |
| CN104693247A (en) * | 2015-01-22 | 2015-06-10 | 武汉市第一医院 | Method for preparing Bletilla striata gelatin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101711159B (en) | Oligo-guluronate and galacturonate compositions | |
| AU2014305430B2 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| CN102091084B (en) | Compound capsule and preparation method thereof | |
| CN104069228B (en) | A bioadhesive microsphere with core-shell structure and preparation method thereof | |
| CN110200926A (en) | Composite reactive freeze-dried powder and its preparation method and application | |
| CN101537008A (en) | Livestock cefquinome bletilla striata bioadhesive slow-release capsules | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101023961B (en) | Medicine composition containing sodium hyaluronate and zinc salt | |
| CN110935007A (en) | Linaclotide compound composition, preparation and use and preparation method thereof | |
| KR20200144568A (en) | Drugs, combination products, and applications for preventing and/or treating pain and/or fever | |
| CN1985949A (en) | Slow released capsule of cefradine and bletilla tuber glue for animal and birds | |
| CN1985958A (en) | Slow released capsule of netilmicin sulfate and bletilla tuber glue for animal and birds | |
| CN1985952A (en) | Slow released capsule of cefazolin sodium and bletilla tuber glue for animal and birds | |
| CN1985959A (en) | Slow released capsule of lindamycin sodium and bletilla tuber glue for animal and birds | |
| CN1985954A (en) | Slow released capsule of lincomycin and bletilla tuber glue for animal and birds | |
| CN1985955A (en) | Slow released capsule of amphotericin B and bletilla tuber glue for animal and birds | |
| CN1985960A (en) | Slow released capsule of clarithromycin and bletilla tuber glue for animal and birs | |
| CN1985956A (en) | Slow released capsule of tobramycin and bletilla tuber glue for animal and birds | |
| CN1985950A (en) | Slow released capsule of cefotaxime sodium and bletilla tuber glue for animal and birds | |
| CN1985951A (en) | Slow released capsule of cefalotin sodium and bletilla tuber glue for animal and birds | |
| CN1985957A (en) | Slow released capsule of sparfloxacin and bletilla tuber glue for animal and birds | |
| CN1985948A (en) | Slow released capsule of cefoperazone and bletilla tuber glue for animal and birds | |
| CN1985953A (en) | Slow released capasule of ofloxacin and bletilla tuber glue for animal and birds | |
| CN102240314A (en) | Medicine for treating urinary tract infection | |
| CN112870212B (en) | Application of Anoectochilus roxburghii glycoside in preparation of medicine for preventing and/or treating pulmonary fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090923 |